08:13:02 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Bonesupport är verksamma inom medicinteknik. Bolaget utvecklar och kommersialiserar injicerbara biokeramiska bengraftsubstitut som ombildas till patientens eget ben och har förmåga att frisätta läkemedel. Bolagets bengraftsubstitut är baserade på teknologiplattformen Cerament. I dagsläget genomför bolaget löpande kliniska studier. Bolaget innehar försäljning i Europa och Nordamerika och huvudkontoret ligger i Lund.

Kalender

2022-10-27 Kvartalsrapport 2022-Q3
2022-07-14 Kvartalsrapport 2022-Q2
2022-05-20 Ordinarie utdelning BONEX 0.00 SEK
2022-05-19 Årsstämma 2022
2022-05-04 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-07-15 Kvartalsrapport 2021-Q2
2021-05-21 Ordinarie utdelning BONEX 0.00 SEK
2021-05-20 Årsstämma 2021
2021-05-06 Kvartalsrapport 2021-Q1
2021-02-17 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-07-17 Kvartalsrapport 2020-Q2
2020-05-20 Ordinarie utdelning BONEX 0.00 SEK
2020-05-19 Årsstämma 2020
2020-05-08 Kvartalsrapport 2020-Q1
2020-02-26 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-07-25 Kvartalsrapport 2019-Q2
2019-05-15 Ordinarie utdelning BONEX 0.00 SEK
2019-05-14 Årsstämma 2019
2019-05-02 Kvartalsrapport 2019-Q1
2019-02-27 Bokslutskommuniké 2018
2018-11-07 Kvartalsrapport 2018-Q3
2018-07-26 Kvartalsrapport 2018-Q2
2018-05-23 Ordinarie utdelning BONEX 0.00 SEK
2018-05-22 Årsstämma 2018
2018-05-04 Kvartalsrapport 2018-Q1
2018-02-20 Bokslutskommuniké 2017
2017-11-02 Kvartalsrapport 2017-Q3
2017-08-17 Kvartalsrapport 2017-Q2
2022-05-18 08:24:00

BONESUPPORT ™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company has received market authorization from the US Food and Drug Administration (FDA), for the company's antibiotic eluting product CERAMENT G, for the indication bone infection (osteomyelitis).

CERAMENT G has received market authorization through a De Novo process, which is one of the regulatory pathways available when there is no previous comparable product (“predicate device”) legally marketed. CERAMENT G has been given “Breakthrough device” categorization by FDA, as it adds significant clinical value compared to existing treatment options by enabling natural bone healing protected by locally eluted antibiotics, in a one-stage-procedure. CERAMENT G has been proven to significantly improve the treatment outcomes for patients suffering from bone infection, with a reduced risk of reinfection and amputation.

CERAMENT G is the first and only bone graft, with antibiotic elution, approved for the US market

"The announcement from the FDA means that BONESUPPORT achieves the most important milestone in the company's commercial history to date. The benefits of CERAMENT G for patients and clinics, have been validated in several very strong clinical trials, and have paved the way for our strong sales in Europe, where CERAMENT G accounts for a clear majority of our sales," said Emil Billbäck, CEO of BONESUPPORT.

BONESUPPORT estimates that there are 50 k patients treated each year in the US market for bone infections. The market is growing with 5-7% a year.

BONESUPPORT will hold a conference call and an online presentation on May 18 at 11.00 am CEST. The call will be hosted by Emil Billbäck, CEO and Håkan Johansson, CFO who will share details on the FDA approval and answer questions. The presentation will be held in English. 

The dial-in numbers for the conference call are:
SE: +46 856642651 PIN:27492126#
UK: +44 3333000804 PIN:27492126#
US: +1 6319131422 PIN:27492126#

The presentation will be webcasted and can be followed here:
https://tv.streamfabriken.com/bonesupport-press-conference
For more information contact: